Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.
At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).
Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.
Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.
Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.
NeuroPace, a medical device company focused on epilepsy, reported Q1 2022 revenue of $11.4 million, up from $11.2 million in Q1 2021. Initial implant revenue rose to $8.8 million, a significant increase from $8.1 million the previous year. However, replacement implant revenue dropped to $2.6 million from $3.1 million. The company experienced a net loss of $11.5 million, wider than the $8.8 million loss in Q1 2021. For 2022, they project revenue between $45 million and $48 million and a gross margin in the mid-70% range.
NeuroPace, Inc. has commenced the RESPONSE clinical trial, the first study assessing the efficacy of the RNS System for treating drug-resistant focal epilepsy in adolescents aged 12 to 17. Conducted at Westchester Medical Center, this pivotal study aims to confirm the system's safety and effectiveness as an adjunctive therapy. The RNS System is uniquely designed to deliver real-time treatment based on individual brain patterns, offering hope to over 1 million adolescents with epilepsy who are resistant to standard medication.
NeuroPace, Inc. (Nasdaq: NPCE) will release its financial results for Q1 2022 on May 12, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone or webcast on their website. NeuroPace specializes in medical devices for epilepsy treatment, with its RNS System being the first brain-responsive platform delivering timely, personalized therapies. This innovative approach aims to improve care for drug-resistant epilepsy patients and potentially others with brain disorders, enhancing treatment outcomes.
NeuroPace, Inc. (Nasdaq: NPCE) reported a 10% increase in total revenue, reaching $45.2 million for 2021, driven by a 20% rise in initial implant revenue. The fourth quarter revenue was $11.0 million, a 2% increase year-over-year. However, replacement implant revenue declined 19% in Q4. The company received FDA approval for a pivotal study in drug-resistant epilepsy and increased battery life for its RNS System. For 2022, guidance estimates total revenue between $45 million and $48 million.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its financial results for Q4 and full year 2021 on March 10, 2022, post-market. A conference call will follow at 1:30 PM PT. Interested investors can join the call by dialing (844) 955-2173 or (914) 987-7949. CEO Mike Favet and other executives will also present at the SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:00 AM PT. NeuroPace specializes in innovative medical devices for epilepsy treatment, with its RNS System being the first brain-responsive platform for real-time seizure management.
NeuroPace, Inc. (Nasdaq: NPCE) reported preliminary unaudited revenue for Q4 and full-year 2021. Q4 revenue is expected at $11.0 million, a 2% increase year-over-year, with initial implant revenue at $8.5 million (10% growth). However, replacement implant revenue declined by 19% to $2.5 million. Full-year revenue is anticipated at $45.2 million, up 10% from 2020, driven by $33.7 million from initial implants (20% growth), but replacement implant revenue dropped 12% to $11.5 million. NeuroPace plans to present detailed financial results in March 2022.
NeuroPace, a medical device company focused on epilepsy treatment, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. CEO Mike Favet, CFO Rebecca Kuhn, and General Counsel Irina Ridley will present virtually on January 12, 2022, at 8:15 AM PT / 11:15 AM ET. A live webcast and subsequent archived recording will be available for 90 days on the company's website. NeuroPace's RNS System offers a unique, brain-responsive platform aimed at improving the lives of epilepsy patients by delivering real-time treatment.
NeuroPace, a medical device company focused on epilepsy treatment, reported Q3 2021 revenue of $10.3 million, a 19% decrease from last year. Initial implant revenue was $7.8 million, down 15%, influenced by COVID-19 disruptions. The company received IDE approval for a study on drug-resistant epilepsy and submitted a supplement for extending battery life claims of its RNS neurostimulator by two years. Operating expenses increased to $13.8 million, leading to a net loss of $8.1 million. Full-year guidance estimates total revenue between $44 million to $44.5 million.
NeuroPace has received FDA Investigational Device Exemption for its RNS® System to study treatment of drug-resistant idiopathic generalized epilepsy (IGE) in patients aged 12 and older. The NAUTILUS study will be the first in the U.S. to evaluate brain-responsive neuromodulation for IGE treatment, starting patient enrollment in 2022. The RNS System aims to improve life quality by monitoring and responding to patients' unique brain patterns. Previously, it received Breakthrough Device Designation from the FDA for this condition.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will release its third-quarter 2021 financial results on November 10, 2021, after market close. Following the results, the company's management will host a conference call at 1:30 p.m. PT, available via dial-in or through a live webcast on their website. NeuroPace specializes in medical devices aimed at treating epilepsy, utilizing its innovative RNS System which provides personalized neuromodulation therapy to patients with drug-resistant seizures.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
What is NeuroPace, Inc. known for?
What medical condition does the RNS® System primarily target?
Where is NeuroPace, Inc. based?
How does the RNS® System work?
Who are the primary customers for the RNS® System?
What recent achievements has NeuroPace made?
How does NeuroPace generate revenue?
Can the RNS® System treat conditions other than epilepsy?
What makes the RNS® System unique?
Who can be contacted for investor-related inquiries at NeuroPace?
